Amisulpride-induced tardive dyskinesia

Schizophrenia Research

Volumn 88, Issue 1-3, 2006, Pages 232-234

  Fountoulakis, Konstantinos N ^a   Panagiotidis, Panagiotis ^a   Siamouli, Melina ^a   Kantartzis, Sotiris ^a   Mavridis, Theocharis ^a   Iacovides, Apostolos ^a   Kaprinis, George ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Amisulpride; Extrapyramidal symptoms; Tardive dyskinesia

Indexed keywords

AMISULPRIDE; HALOPERIDOL; LEVOMEPROMAZINE; LORAZEPAM; OLANZAPINE; QUETIAPINE;

ADULT; ARTICLE; CASE REPORT; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ELECTROCARDIOGRAM; ELECTROENCEPHALOGRAM; HEBEPHRENIA; HUMAN; LITERATURE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE; TARDIVE DYSKINESIA; THYROID FUNCTION TEST;

ADULT; ANTIPSYCHOTIC AGENTS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG ADMINISTRATION SCHEDULE; DYSKINESIA, DRUG-INDUCED; EXTRAPYRAMIDAL TRACTS; HUMANS; MALE; SULPIRIDE;

EID: 33750615127     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2006.08.001     Document Type: Article

References (11)

1. Casey D. Tardive dyskinesia and atypical antipsychotic drugs. Schizophr. Res. 35 (1999) 61-66 (Suppl)
2. Correll C., Leucht S., and Kane J. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am. J. Psychiatry 161 (2004) 414-425
3. Davis J., Chen N., and Glick I. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry 60 (2003) 553-564
4. Haro J., and Salvador-Carulla L. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia. CNS Drugs 20 4 (2006) 293-301
5. Kane J. Tardive dyskinesia: epidemiological and clinical presentation. In: Bloom F., and Kupfer D. (Eds). Psychopharmacology: The Fourth Generation of Progress (1995), Raven Press, New York 1485-1496
6. Kapur S., and Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: a new hypothesis. Am. J. Psychiatry 158 (2001) 360-369
7. Leucht S., Pitschel-Walz G., Engel R., and Kissling W. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am. J. Psychiatry 159 (2002) 180-190
8. Llorca P., Chereau I., Bayle F., and Lancon C. Tardive dyskinesias and antipsychotics: a review. Eur. Psychiatr. 17 3 (2002) 129-138
9. Naranjo C., Busto U., Sellers E., Sandor P., Ruiz I., and Roberts E. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 30 2 (1981) 239-245
10. Peritogiannis V., Tsouli S., Zafiris S., Pappas D., and Mavreas V. Improvement of tardive dyskinesia following amisulpride treatment. Prog. Neuro-psychopharmacol. Biol. Psychiatry 30 4 (2006) 748-750
11. Seeman P. Atypical antipsychotics: mechanism of action. Can. J. Psychiatry 47 1 (2002) 27-38